Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of “Buy” by Analysts

Quince Therapeutics, Inc. (NASDAQ:QNCX) has been given an average rating of “Buy” by the six research firms that are currently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $9.50.

A number of research firms have weighed in on QNCX. D. Boral Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Quince Therapeutics in a research note on Wednesday, February 5th. Brookline Capital Management began coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They set a “buy” rating and a $9.00 price target on the stock.

Quince Therapeutics Stock Performance

Shares of QNCX opened at $1.38 on Tuesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. The company has a market capitalization of $60.72 million, a price-to-earnings ratio of -1.11 and a beta of 0.71. Quince Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.45. The company’s 50 day simple moving average is $1.50 and its 200 day simple moving average is $1.43.

Institutional Investors Weigh In On Quince Therapeutics

Large investors have recently made changes to their positions in the business. Anfield Capital Management LLC acquired a new stake in shares of Quince Therapeutics in the fourth quarter worth $50,000. Virtu Financial LLC acquired a new stake in shares of Quince Therapeutics in the fourth quarter worth $55,000. Two Sigma Investments LP acquired a new stake in shares of Quince Therapeutics in the fourth quarter worth $57,000. Northern Trust Corp increased its position in shares of Quince Therapeutics by 48.5% in the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock worth $94,000 after acquiring an additional 16,501 shares in the last quarter. Finally, Scharf Investments LLC acquired a new stake in shares of Quince Therapeutics in the fourth quarter worth $170,000. Institutional investors and hedge funds own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.